Country for PR: China
Contributor: PR Newswire Asia (China)
Thursday, December 31 2020 - 12:00
WinHealth and Immedica enter agreement giving Winhealth rights to Ravicti(R) in China and several other Asia-Pacific countries
STOCKHOLM and HANGZHOU, China, Dec. 31, 2020 /PRNewswire-AsiaNet/ --

Hongkong WinHealth Pharma Group CO., Ltd and Immedica Pharma AB, today announce 
that they have entered an agreement under which WinHealth gains the exclusive 
commercial rights to Ravicti(R) (glycerol phenylbutyrate), in a territory 
covering the Greater China Area, South Korea, Singapore, Vietnam, Indonesia, 
Malaysia, Philippines and Thailand. 

Ravicti(R) is in Europe and North America indicated for treatment of urea cycle 
disorders (UCD), and under the announced partnership, WinHealth is granted a 
license to register and commercialize the product in UCD in the countries of 
the specified territory.

"It is with great pleasure that we announce this partnership with WinHealth, 
under which we will be able to make Ravicti(R) available to UCD patients also 
in this part of the world. It also strengthens Immedica's geographical 
footprint, by introducing yet another rare disease collaboration to our 
network", says Anders Edvell, CEO of Immedica.

Torreya acted as a financial advisor to Immedica for this transaction.

Jack Wang, Chairman and CEO of Winhealth, comments, "Urea Cycle Disorder 
represents a severely underserved medical need in China, resulting in severe 
neurocognitive decline, coma or even death, if left untreated. We are very 
excited to partner up with Immedica and look forward to bringing Ravicti®, an 
innovative therapeutic approved both in Europe and the United States, to the 
patients suffering from UCD in China and adjacent countries."

About Urea Cycle Disorders (UCD)

The urea cycle is a process in which waste (ammonia) is removed from the body. 

Several inherited conditions can cause problems with this waste-removal 
process. People with a urea cycle disorder are missing a gene that makes the 
enzymes needed to break down ammonia in the body. As a group, these disorders 
occur in 1 in 30,000 newborns in the territories where Immedica has acquired 

Typically, symptoms such as confusion, nausea, vomiting, decreased food intake 
and increased sleepiness occur within the first week after birth.

About Immedica

Immedica is a fast-growing private European niche pharma group. Its headquarter 
is based in Stockholm, Sweden, and the company has direct pan-European and 
Middle East commercial coverage. In addition, Immedica provides some of its 
products to other parts of the world via a network of regional partners.

Immedica provides significant know-how and experience from commercialization of 
niche/specialty care products across Europe and the Middle East, and the 
company's management team has an outstanding track record of partnering and 
operating niche pharma products internationally. Immedica has capabilities to 
provide optimal access of specialty care medicines to patients with significant 
medical needs, including key areas such as regulatory affairs, 
pharmacovigilance, medical affairs, pricing & reimbursement, and product 

About WinHealth

WinHealth Pharma is a commercial-stage biopharmaceutical company aiming at 
fulfilling severely unmet or underserved medical needs for patients with rare 
diseases and other critical medical conditions in China and surrounding 
regions. Since its inception, WinHealth has been committed to sourcing, 
developing, and commercializing innovative therapies from leading biotech and 
pharmaceutical companies worldwide. Winhealth has established long-term 
strategic partnerships with a variety of leading international firms and 
successfully built a diversified pipeline consisting of both clinical-stage and 
commercial-stage products. In addition to its strong development and regulatory 
capabilities, WinHealth has established an industry-leading commercial 
infrastructure covering China and adjacent markets, providing patients with 
faster access to novel therapeutics globally. 


WinHealth Pharma Group CO., Ltd.
Oliver Hao – CO-CEO   
Phone: +86 18602108327

SOURCE:  Winhealth Pharma Group HK